A company with a drug reported to improve cystic fibrosis symptoms, Vertex Pharmaceuticals, notices large jumps in share value because of this new drug.
The drug, VX-770, has shown through trial studies, that it may effectively benefit various lung functions for individuals suffering from cystic fibrosis.
Shares of the company are up more than 15 percent.
This value increase is the first the company has experienced in nearly 5 years, and much of the jump is attributed to this new drug.
Experts explain that if the VX-770 drug were to be approved, it could notice sales above the $500 million mark.
In trial studies, the drug showed to increase lung function in many cystic fibrosis patients, in some cases more than 10 percent.
While some medical experts believe this drug may not be beneficial to each and every cystic fibrosis patient, others explain that because of the potential benefits it can show, the drug may drastically influence how cystic fibrosis is treated in the future.